The total value of awards made by the Executive Board of the Health Ministers' Council for Gulf Corporation Council States on pharmaceutical tender 16 and vaccines tender 9 was $295 million, an increase of 74% on the previous year. The GCC, which was was formed in 1981, comprises Saudi Arabia, Bahrain, Kuwait, Qatar, Oman and the United Arab Emirates.
Saudi Arabia dominates the purchases made by the six member countries, accounting for 73% of the total combined tenders in 1994, according to IMS' Pharma Strategy Group; despite the EB's move to two-year tendering, however, Saudi Arabia's purchases have increased by only 60%, implying that it will have drug requirements in the second year of the duration of the tender.
Qatar bought only two items in 1993 (pharmaceutical tender 15 and vaccines tender 8) worth a total of $1,737, but for 1994 it is the second largest purchasing country, with nearly 10% of the total tender value.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze